Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, randomized, dose finding and dose expansion study to
evaluate the safety, preliminary efficacy, and PK of gedatolisib in combination with
darolutamide in subjects with mCRPC.